SkinHealth Systems Inc. SKIN
The Beauty Health Company (the "Company" or "we") is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.
Hydrafacial is our flagship brand and cornerstone of our portfolio.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- Americas
- Europe, the Middle East and Africa
- Asia-Pacific
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Americas | $204.0M | $217.0M | $227.7M |
| Europe, the Middle East and Africa | $68.3M | $71.6M | $88.1M |
| Asia-Pacific | $28.5M | $45.7M | $82.2M |
As the company reported it, from the “Segment, Geographic, and Other Information - Schedule of Net Sales by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300.8M | $334.3M | $398.0M | $365.9M | $260.1M | $119.1M | $166.6M | — |
| Cost of revenue | $104.4M | $152.0M | $242.9M | $117.1M | $81.5M | $51.9M | $60.1M | — |
| Gross profit | $196.4M | $182.3M | $155.1M | $248.8M | $178.5M | $67.2M | $106.5M | — |
| R&D | $5.6M | $6.3M | $10.1M | $8.4M | $8.2M | $3.4M | $4.6M | — |
| SG&A | $117.9M | $125.5M | $131.4M | $106.1M | $98.7M | $30.6M | $26.7M | — |
| Total operating expenses | $217.2M | $250.1M | $286.0M | $274.6M | $218.5M | $84.4M | $93.0M | — |
| Operating income | -$20.8M | -$67.8M | -$130.9M | -$25.8M | -$39.9M | -$17.2M | $13.5M | — |
| Interest expense | $19.3M | $10.4M | $13.6M | $13.4M | $11.8M | — | — | — |
| Pre-tax income | -$5.9M | -$29.6M | -$101.9M | $45.3M | -$380.6M | -$38.5M | -$2.9M | — |
| Income tax | $3.6M | $452.0K | $1.8M | $1.1M | $1.9M | $9.3M | $1.3M | — |
| Net income | -$9.5M | -$29.1M | -$100.1M | $44.2M | $378.7M | -$29.2M | -$1.6M | — |
| EPS, basic | -0.08 | -0.23 | -0.76 | 0.30 | -3.71 | -0.85 | -0.05 | — |
| EPS, diluted | -0.16 | -0.36 | -0.76 | -0.23 | -3.71 | -0.85 | -0.05 | — |
| Shares, diluted (wtd. avg.) | 135.8M | 142.5M | 131.7M | 148.5M | 102.1M | 34.3M | 32.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $232.7M | $370.1M | $523.0M | $568.2M | $901.9M | $9.5M | $7.3M | $3.6M |
| Receivables | $21.7M | $27.6M | $54.7M | $76.5M | $46.8M | $18.6M | — | — |
| Inventory | $48.0M | $69.1M | $91.3M | $109.7M | $35.3M | $23.2M | — | — |
| Total current assets | $309.5M | $477.1M | $698.3M | $783.3M | $1.00B | $59.1M | — | — |
| Property, plant and equipment | — | — | — | — | — | $9.2M | — | — |
| Goodwill | $126.6M | $123.5M | $125.8M | $124.6M | $123.7M | $98.5M | $98.5M | $98.1M |
| Other intangibles | $35.8M | $47.5M | $62.1M | $46.4M | $56.0M | $50.9M | — | — |
| Total assets | $499.8M | $685.7M | $929.1M | $1.00B | $1.22B | $222.8M | — | — |
| Accounts payable | $15.6M | $21.9M | $44.8M | $28.5M | $29.0M | $18.5M | — | — |
| Total current liabilities | $186.3M | $68.2M | $115.0M | $71.7M | $76.4M | $30.9M | — | — |
| Total liabilities | $438.7M | $633.9M | $869.7M | $836.0M | $916.5M | $252.8M | — | — |
| Retained earnings | -$517.5M | -$508.0M | -$478.9M | -$378.8M | -$418.7M | -$43.6M | — | — |
| Total equity | $61.1M | $51.8M | $59.4M | $167.1M | $298.0M | -$30.6M | -$1.2M | $294.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $37.5M | $16.1M | $21.8M | -$106.6M | -$28.4M | -$12.4M | $1.7M | — |
| Depreciation and amortisation | $3.8M | $9.9M | $11.3M | $7.2M | $4.5M | $2.6M | $1.4M | — |
| Stock-based compensation | $14.8M | $26.7M | $22.5M | $28.5M | $12.4M | $363.0K | $103.0K | — |
| Capital expenditure | $303.0K | $756.0K | $3.8M | $10.8M | $11.2M | $3.5M | $8.8M | — |
| Investing cash flow | -$5.2M | -$6.8M | -$31.5M | -$18.9M | -$37.7M | -$3.8M | -$12.5M | — |
| Financing cash flow | -$174.9M | -$158.3M | -$37.4M | -$205.2M | $959.0M | $18.3M | $14.6M | — |
| Buybacks | $0 | $0 | $30.2M | $160.0M | $0 | $154.0K | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-003189.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $166.6M | $119.1M | $260.1M | $365.9M | $398.0M | $334.3M | $300.8M |
| Gross profit | — | $106.5M | $67.2M | $178.5M | $248.8M | $155.1M | $182.3M | $196.4M |
| Net income | — | -$1.6M | -$29.2M | $378.7M | $44.2M | -$100.1M | -$29.1M | -$9.5M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.42B | 36.4x | 11.2% |
| MMM | 3M CO | $89.11B | 28.8x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.06B | 23.5x | 19.9% |
| BDX | BECTON DICKINSON & CO | $53.49B | 33.7x | 8.2% |
| RMD | RESMED INC | $36.52B | 24.3x | 9.9% |
| DXCM | DEXCOM INC | $29.65B | 37.6x | 15.6% |
| MDLN | Medline Inc. | $28.86B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.78B | 58.1x | 6.3% |